Watch DARE. Know when insiders buy.
One email the day a filing lands. Free.
DARE
Dare Bioscience, Inc.
0.70
−0.01 −1.67%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.8MP/E —DIV YIELD —FCF YIELD -109.06%REV TTM $1.4M −7816.7%NET INCOME −$11MNET CASH $12.6M52W 0.70 – 3.27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $188K | — | -70.6% | −$3M | −$3M | — | -0.20 | −$6.8M | $81K | −$6.9M | Aug 13 |
| Q1 2026 · Mar 31 | $152K | +499.6% | -58.9% | −$3M | −$3M | — | -0.21 | −$5.5M | $0 | −$5.5M | Aug 13 |
| Q4 2025 · Dec 31derived | $1M | — | — | −$1.5M | −$1.4M | — | -0.02 | $1.4M | $207K | $1.2M | Mar 26 |
| Q3 2025 · Sep 30 | $2K | −94.6% | — | −$3.7M | −$3.6M | — | -0.28 | −$442K | $175K | −$617K | Nov 13 |
| Q2 2025 · Jun 30 | −$21K | −194.4% | 100.0% | −$3.8M | −$4M | −131.1% | -0.45 | −$5.4M | −$153K | −$5.3M | Aug 13 |
| Q1 2025 · Mar 31 | $25K | +173.3% | 100.0% | −$4.6M | −$4.4M | — | -0.50 | −$5.5M | $157K | −$5.6M | Aug 13 |
| Q4 2024 · Dec 31derived | −$64K | −103.5% | — | −$5.4M | −$5.5M | — | -0.65 | $5.3M | $563K | $4.7M | Mar 26 |
| Q3 2024 · Sep 30 | $42K | −95.8% | — | −$4.7M | −$4.7M | — | -0.55 | −$5.9M | −$282K | −$5.6M | Nov 13 |
| Q2 2024 · Jun 30 | $22K | — | — | −$7.4M | $12.9M | — | 1.52 | $12.9M | $285K | $12.6M | Nov 13 |
| Q1 2024 · Mar 31 | $9K | — | — | −$6M | −$6.8M | — | -0.81 | −$6.8M | $7K | −$6.8M | Nov 13 |
| Q4 2023 · Dec 31derived | $1.8M | — | — | −$5.2M | −$5.1M | — | -0.70 | −$8.2M | $607K | −$8.8M | Mar 31 |
| Q3 2023 · Sep 30 | $1M | — | — | −$8.4M | −$8.3M | — | -1.09 | −$8M | $22K | −$8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1M | 71.3% | −$13.6M | −$13.4M | -1300.7% | -1.20 | −$9.9M | $385K | −$10.3M | — | — |
| FY2024 · to Dec 31 | $10K | 100.0% | −$23.5M | −$4.1M | -41430.9% | -0.48 | $5.5M | $573K | $4.9M | — | — |
| FY2023 · to Dec 31 | $2.8M | — | −$30.9M | −$30.2M | -1074.2% | -4.15 | −$38.9M | $629K | −$39.5M | — | — |
| FY2022 · to Dec 31 | $10M | — | −$31.4M | −$30.9M | -309.5% | -0.37 | −$18.1M | $63K | −$18.2M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$39.1M | −$38.7M | — | -0.63 | −$28.8M | $15K | −$28.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$27.4M | −$27.4M | — | -0.91 | −$25.2M | $18K | −$25.3M | — | — |
Every number comes from Dare Bioscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.